| http://dbpedia.org/ontology/abstract
|
Faricimab ist ein Arzneistoff zur Behandlu … Faricimab ist ein Arzneistoff zur Behandlung bestimmter Erkrankungen der Netzhaut des Auges. Unter dem Handelsnamen Vabysmo (Hersteller: Genentech) wurde Faricimab von der amerikanischen Behörde FDA im Januar 2022 in den USA zugelassen für die Therapie der neovaskulären (feuchten) altersbedingten Makuladegeneration (neovascular (wet) age-related macular degeneration, nAMD) und des diabetischen Makulaödems (diabetic macular edema, DME). Faricimab ist ein monoklonaler Antikörper, der bispezisch wirkt. Das Medikament wird in den Glaskörper des Auges (intravitreal) injiziert.körper des Auges (intravitreal) injiziert.
, Faricimab, sold under the brand name Vabys … Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist. Faricimab was developed by Roche. Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.d in the European Union in September 2022.
, Фарицимаб — лекарственный препарат, моноклональноe антитело для лечения возрастной макулярной дегенерации. Одобрен для применения: США (2022)
|
| http://dbpedia.org/ontology/alternativeName
|
Vabysmo
|
| http://dbpedia.org/ontology/casNumber
|
1607793-29-2
|
| http://dbpedia.org/ontology/drugbank
|
DB15303
|
| http://dbpedia.org/ontology/fdaUniiCode
|
QC4F7FKK7I
|
| http://dbpedia.org/ontology/kegg
|
D11516
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Antibodyigg.png?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/faricimab +
|
| http://dbpedia.org/ontology/wikiPageID
|
58563686
|
| http://dbpedia.org/ontology/wikiPageLength
|
17779
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1118774209
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Hypersensitivity +
, http://dbpedia.org/resource/Angiopoietin_2 +
, http://dbpedia.org/resource/Intravitreal_injection +
, http://dbpedia.org/resource/VEGF-A +
, http://dbpedia.org/resource/Endothelium +
, http://dbpedia.org/resource/Macular_degeneration +
, http://dbpedia.org/resource/Age-related_macular_degeneration +
, http://dbpedia.org/resource/Vascular_endothelial_growth_factor +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Category:Ophthalmology_drugs +
, http://dbpedia.org/resource/Retina +
, http://dbpedia.org/resource/Indicated +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Endothelial_cells +
, http://dbpedia.org/resource/Aflibercept +
, http://dbpedia.org/resource/Drug_development +
, http://dbpedia.org/resource/Pregnancy +
, http://dbpedia.org/resource/Phase_III_clinical_research +
, http://dbpedia.org/resource/Category:Hoffmann-La_Roche_brands +
, http://dbpedia.org/resource/Category:Angiogenesis_inhibitors +
, http://dbpedia.org/resource/Ophthalmologist +
, http://dbpedia.org/resource/Age_related_macular_degeneration +
, http://dbpedia.org/resource/Ranibizumab +
, http://dbpedia.org/resource/Uveitis +
, http://dbpedia.org/resource/Angiopoietin +
, http://dbpedia.org/resource/Vascular_endothelial_growth_factor_A +
, http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/Diabetic_macular_edema +
, http://dbpedia.org/resource/Conjunctiva +
, http://dbpedia.org/resource/Central_retinal_vein_occlusion +
, http://dbpedia.org/resource/Branch_retinal_vein_occlusion +
, http://dbpedia.org/resource/Hoffmann-La_Roche +
, http://dbpedia.org/resource/Preclinical_development +
, http://dbpedia.org/resource/Infection +
, http://dbpedia.org/resource/Category:Genentech_brands +
, http://dbpedia.org/resource/Bispecific_monoclonal_antibody +
, http://dbpedia.org/resource/Visual_acuity +
|
| http://dbpedia.org/property/atcPrefix
|
None
|
| http://dbpedia.org/property/c
|
6506
|
| http://dbpedia.org/property/casNumber
|
1607793
|
| http://dbpedia.org/property/dailymedid
|
Faricimab
|
| http://dbpedia.org/property/drugbank
|
DB15303
|
| http://dbpedia.org/property/h
|
9968
|
| http://dbpedia.org/property/kegg
|
D11516
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalCaComment
|
/Schedule D
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1724
|
| http://dbpedia.org/property/o
|
1026
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravitreal_injection +
|
| http://dbpedia.org/property/s
|
45
|
| http://dbpedia.org/property/source
|
zu
|
| http://dbpedia.org/property/synonyms
|
RO6867461; RG7716; faricimab-svoa
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/VEGF-A +
, http://dbpedia.org/resource/Angiopoietin_2 +
|
| http://dbpedia.org/property/tradename
|
Vabysmo
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
QC4F7FKK7I
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Use_American_English +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:ClinicalTrialsGov +
, http://dbpedia.org/resource/Template:Ocular_vascular_disorder_agents +
, http://dbpedia.org/resource/Template:Monoclonals_for_bone%2C_musculoskeletal%2C_circulatory%2C_and_neurologic_systems +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Nbsp +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Growth_factor_receptor_modulators +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Genentech_brands +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Category:Hoffmann-La_Roche_brands +
, http://dbpedia.org/resource/Category:Angiogenesis_inhibitors +
, http://dbpedia.org/resource/Category:Ophthalmology_drugs +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Faricimab?oldid=1118774209&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Antibodyigg.png +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Faricimab +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q60785557 +
, https://global.dbpedia.org/id/9KcoY +
, http://dbpedia.org/resource/Faricimab +
, http://ru.dbpedia.org/resource/%D0%A4%D0%B0%D1%80%D0%B8%D1%86%D0%B8%D0%BC%D0%B0%D0%B1 +
, http://de.dbpedia.org/resource/Faricimab +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Drug +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Faricimab, sold under the brand name Vabys … Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.ction into the eye) by an ophthalmologist.
, Faricimab ist ein Arzneistoff zur Behandlu … Faricimab ist ein Arzneistoff zur Behandlung bestimmter Erkrankungen der Netzhaut des Auges. Unter dem Handelsnamen Vabysmo (Hersteller: Genentech) wurde Faricimab von der amerikanischen Behörde FDA im Januar 2022 in den USA zugelassen für die Therapie der neovaskulären (feuchten) altersbedingten Makuladegeneration (neovascular (wet) age-related macular degeneration, nAMD) und des diabetischen Makulaödems (diabetic macular edema, DME). Faricimab ist ein monoklonaler Antikörper, der bispezisch wirkt. Das Medikament wird in den Glaskörper des Auges (intravitreal) injiziert.körper des Auges (intravitreal) injiziert.
, Фарицимаб — лекарственный препарат, моноклональноe антитело для лечения возрастной макулярной дегенерации. Одобрен для применения: США (2022)
|
| rdfs:label |
Faricimab
, Фарицимаб
|
